MC

534.3

+1.25%↑

CABK

11.42

+0.4%↑

INGA

26.145

+0.15%↑

NDA.FI

16.83

-0.36%↓

BKT

14.84

+0.95%↑

MC

534.3

+1.25%↑

CABK

11.42

+0.4%↑

INGA

26.145

+0.15%↑

NDA.FI

16.83

-0.36%↓

BKT

14.84

+0.95%↑

MC

534.3

+1.25%↑

CABK

11.42

+0.4%↑

INGA

26.145

+0.15%↑

NDA.FI

16.83

-0.36%↓

BKT

14.84

+0.95%↑

MC

534.3

+1.25%↑

CABK

11.42

+0.4%↑

INGA

26.145

+0.15%↑

NDA.FI

16.83

-0.36%↓

BKT

14.84

+0.95%↑

MC

534.3

+1.25%↑

CABK

11.42

+0.4%↑

INGA

26.145

+0.15%↑

NDA.FI

16.83

-0.36%↓

BKT

14.84

+0.95%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

183.8 -5.28

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

182.7

Max

193.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

64M

Pardavimai

-39M

706M

P/E

Sektoriaus vid.

69.096

27.185

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

9.097

Darbuotojai

10,134

EBITDA

16M

218M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+30.04% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2B

18B

Ankstesnė atidarymo kaina

189.08

Ankstesnė uždarymo kaina

183.8

Naujienos nuotaikos

By Acuity

9%

91%

11 / 445 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 23:11; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

2026-02-03 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-03 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting All-Time High -- Market Talk

2026-02-03 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-02-03 23:41; UTC

Įsigijimai, susijungimai, perėmimai

KKR Makes AI Play With $10.9B Asia Data-Center Deal

2026-02-03 23:38; UTC

Uždarbis

AMD Sales Climb on Help From Data-Center Business -- Update

2026-02-03 23:29; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

2026-02-03 23:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

2026-02-03 23:25; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Consortium Expects Deal to Close by Early 2H of 2026

2026-02-03 23:23; UTC

Įsigijimai, susijungimai, perėmimai

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

2026-02-03 23:22; UTC

Įsigijimai, susijungimai, perėmimai

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

2026-02-03 23:19; UTC

Rinkos pokalbiai

Australia Gold Miners Tipped to Rally Higher -- Market Talk

2026-02-03 23:19; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-03 22:56; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

2026-02-03 22:40; UTC

Uždarbis

Amdocs Extends Collaboration With T-Mobile

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Adj EPS $1.81

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q Rev $1.16B

2026-02-03 22:39; UTC

Uždarbis

Amdocs 1Q EPS $1.45 >

2026-02-03 22:38; UTC

Uždarbis

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

2026-02-03 22:30; UTC

Įsigijimai, susijungimai, perėmimai

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

2026-02-03 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

2026-02-03 22:14; UTC

Uždarbis

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

2026-02-03 22:13; UTC

Uždarbis

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

2026-02-03 22:12; UTC

Uždarbis

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

2026-02-03 22:10; UTC

Uždarbis

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

2026-02-03 22:10; UTC

Rinkos pokalbiai

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

2026-02-03 22:10; UTC

Uždarbis

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

2026-02-03 22:09; UTC

Uždarbis

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

30.04% į viršų

12 mėnesių prognozė

Vidutinis 243.5 EUR  30.04%

Aukščiausias 260 EUR

Žemiausias 220 EUR

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

3

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

11 / 445 reitingas Finansų sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat